This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mook, O. R. Articles by Fluiter, K. Search for Related Content PubMed PubMed Citation Articles by Mook, O. R. Articles by Fluiter, K.

Research Articles: Therapeutics, Targets, and Development

Evaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo

Department of Neurogenetics, Academic Medical Center, Amsterdam, the Netherlands

Requests for reprints: Olaf R. Mook, Department of Neurogenetics, Academic Medical Center, Meibergdreef 9, Amsterdam, the Netherlands 1105 AZ. Phone: 312-056-64540. E-mail: o.r.mook{at}amc.uva.nl

Abstract

RNA interference has become widely used as an experimental tool to study gene function. In addition, small interfering RNA (siRNA) may have great potential for the treatment of diseases. Recently, it was shown that siRNA can be used to mediate gene silencing in mouse models. Locally administered siRNAs entered the first clinical trials, but strategies for successful systemic delivery of siRNA are still under development. Challenges still exist about the stability, delivery, and therapeutic efficacy of siRNA. In the present study, we compare the efficacy of two methods of systemic siRNA delivery and the effects of siRNA modifications using locked nucleic acids (LNA) in a xenograft cancer model. Low volume tail vein bolus injections and continuous s.c. delivery using osmotic minipumps yielded similar uptake levels of unmodified siRNA by tumor xenografts. Both routes of administration mediated sequence-specific inhibition of two unrelated targets inside tumor xenografts. Previous studies have shown that LNA can be incorporated into the sense strand of siRNA while the efficacy is retained. Modification of siRNA targeting green fluorescent protein with LNA results in a significant increase in serum stability and thus may be beneficial for clinical applications. We show that minimal 3' end LNA modifications of siRNA are effective in stabilization of siRNA. Multiple LNA modifications in the accompanying strand further increase the stability but negate the efficacy in vitro and in vivo. In vivo, LNA-modified siRNA reduced off-target gene regulation compared with nonmodified siRNA. End-modified siRNA targeting green fluorescent protein provides a good trade-off between stability and efficacy in vivo using the two methods of systemic delivery in the nude mouse model. Therefore, LNA-modified siRNA should be preferred over unmodified siRNA. [Mol Cancer Ther 2007;6(3):833–43]

Grant support: Dutch Cancer Society project no. 2003-2968.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ http://rsb.info.nih.gov/ij/

Received 4/10/06; revised 11/23/06; accepted 1/31/07.